Replies to post #323744 on Avid Bioservices Inc (CDMO)

[north40000]

Good that you remember what I remember, thanks.

This ESMO slide that jdm1 found comes close but not the right one:

https://cslide.ctimeetingtech.com/library/esmo/browse/search/5uD#2Bb5o0JE

"... In an exploratory analysis of OS for patients who received subsequent immune checkpoint inhibitors (ICI), the mOS was not reached (95% CI, 15.2-NA) in B+D (n?=?46) and 12.6 months (95% CI, 10.4-17.8) in D (n?=?47) (HR, 0.46; P?=?0.006).

Conclusions
The combination of B+D was well-tolerated though no OS difference was observed compared to D alone in the ITT population of previously treated nonsquamous NSCLC. An exploratory analysis of patients who received subsequent ICI found significantly longer OS in patients who received prior B+D than those who received D and support further clinical investigation of B+ICI in NSCLC.